latest news releases from the newsroom
Basilea Pharmaceutica Ltd
Basilea Reports Positive Phase III Results for Alitretinoin
BASEL, Switzerland, Feb. 19, 2007 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that its placebo-controlled pivotal phase III BACH trial (Benefit of Alitretinoin in Chronic Hand dermatitis) successfully met its primary objective. Alitretinoin was effective in patients suffering from severe and refractory chronic hand dermatitis, as determined by the stringent endpoint of clear and almost clear hands. Currently, no approved treatment exists for this debilitating disease which prevents patients from using their hands normally. These positive data will form the basis of regulatory submissions later this year.
Converium Holding AG
Converium Rejects Unsolicited Proposal by SCOR
ZUG, Switzerland, Feb. 19, 2007 (PRIME NEWSWIRE) -- The Board of Directors of Converium, who is being advised by Credit Suisse and JPMorgan, has carefully considered an unsolicited proposal by SCOR, over the weekend, to acquire Converium at CHF 21.- per share. The Directors are unanimous in their rejection of this proposal, which they believe fundamentally fails to recognise the value of Converium's franchise and growth prospects, and is, therefore, not in the interest of Converium, its shareholders, and its customers.